Altimmune, Inc., a clinical-stage biopharma company, has expanded its AdCOVID manufacturing collaboration with Lonza, under which Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for COVID-19, at its facility near Houston, TX.   AdCOVID, administered via nasal spray, was shown to activate systemic immunity (neutralizing antibodies and T cell responses) and mucosal immunity in the respir...